期刊文献+

来氟米特联合激素治疗中青年女性IgA肾病的临床疗效

原文传递
导出
摘要 目的:探讨来氟米特联合激素治疗中青年女性IgA肾病(IgAN)的疗效和安全性。方法:选择40例中青年女性IgAN住院患者,20例为治疗组[来氟米特+激素+血管紧张素转换酶抑制剂(ACEI)],20例为对照组(单纯应用ACEI),用药期间监测24 h尿蛋白定量、血白蛋白、平均动脉压、血肌酐、血白细胞、血小板等,观察两组疗效和不良反应。结果:治疗组治疗后24 h尿蛋白定量明显下降(P<0.05),血白蛋白明显上升(P<0.05),完全缓解和显效的比例(80%)明显高于对照组(50%),差异有统计学意义(P<0.05)。治疗组较对照组起效快。结论:来氟米特联合激素治疗中青年女性IgAN在降低尿蛋白及升高白蛋白方面显著优于单用ACEI,且副作用小,值得临床推广应用。
出处 《中国妇幼保健》 CAS 北大核心 2009年第34期4929-4930,共2页 Maternal and Child Health Care of China
  • 相关文献

参考文献6

  • 1Barratt J, Feehally J. Treatment of IgA nephropathy [J] . Kidney Int, 2006, 69 (11): 1934.
  • 2Bartlett RR, Brendel S, Zieliash T et al. Leflunomide: an imunorestoring drug for the therapy of autoimmune disorders, especially, rheumatoid arthritis [J]. Transplant Proc, 1996, 2 (6): 3074.
  • 3Xu X, Shen J, Mall JW et al. In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action [J] . Bioehem Pharmaeol, 1999, 58 (9) : 1405.
  • 4Imose, Motoaki, Nagaki et ul. Leflunomiide protects from T- cell - mediated liver injury in mice through inhibition of nuclear factor kappa B [J] .Hepatology, 2004, 40 (5): 1160.
  • 5Johannes G, Daniela E, Marcus DK et al. Leflunomide reduces transendothelial migration [ J]. Arthritis Rheumatism, 2001, 44 (9) : 297.
  • 6杨光,唐政.来氟米特在肾脏疾病中的应用[J].国外医学(泌尿系统分册),2004,24(5):652-655. 被引量:14

二级参考文献18

  • 1Kalden J,Schattenkirchner M,Sorensen H,et al.Five year follow-up:efficacy and safety of leflunomide in patients with active rhrumatoid arthritis.Arthritis & Rheumatism,2001,44(9):173-176.
  • 2Hansen KE,Cush J,Singhal A,et al.The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis.Arthritis Rheum,2004,51(2):228-232.
  • 3Jaimes-Hernandez J,Robles-San Roman M,et al.Rheumatoid arthritis treatment with weekly leflunomide:an open-label study.J Rheumatol,2004,31(2):235-237.
  • 4Williams JW,Mital D,Chong A,et al.Experiences with leflunomide in solid organ transplantation.Transplantation,2002,73(3):358-366.
  • 5Xu X,Shen J,Mall JW,et al.In vitro and in vivo antitumor activity of a novel immunomodulatory drug,leflunomide:mechanisms of action.Biochem Pharmacol,1999,58(9):1405-1413.
  • 6Manna SK,Aggarwal BB.Immunosuppressive leflunomide metabolite(A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.J Immunol,1999,162(4):2095-2102.
  • 7Urushibara M,Takayanagi H,Koga T,et al.The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.Arthritis Rheum,2004,50(3):794-804.
  • 8Miceli-Richard C,Dougados M.Leflunomide for the treatment of rheumatoid arthritis.Expert Opin Pharmacother,2003,4(6):987-997.
  • 9Petya Dimitrova,Alla Skapenko,Rudolf Schleyerbach,et al.Immunomodulatory functions of leflonomide:inhibition of T helper(TH)1 cell activation and promotion of TH2 differentiation.Arthritis & Rheumatism,2001,44(9):216-221.
  • 10Johannes Grisar,Daniela Eselbock,Marcus D Koller,et al.Leflunomide reduces transendothelial migration.Arthritis & Rheumatism,2001,44(9):297-303.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部